Evidence map›Paper›PMID 28255359›Full record

ArticleTheranostics2017

Targeting and Regulating of an Oncogene via Nanovector Delivery of MicroRNA using Patient-Derived Xenografts.

Shuyang Sun, Yilong Wang, Rong Zhou, Zicheng Deng, Yong Han, Xiao Han, Wenjie Tao, Zi Yang, Chaoji Shi, Duo Hong and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Role of microRNAs in the pathophysiology of addiction.Wiley interdisciplinary reviews. RNA · 2021
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.The Journal of pharmacology and experimental therapeutics · 2023
    Review
  13. Role of Nano-miRNAs in Diagnostics and Therapeutics.International journal of molecular sciences · 2022
    Review
  14. Review
  15. Article
  16. Nanoparticle Delivery Systems with Cell-Specific Targeting for Pulmonary Diseases.American journal of respiratory cell and molecular biology · 2021
    Review
  17. Recent Advances in miRNA Delivery Systems.Methods and protocols · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Shuyang SunDepartment of Oral and Maxillofacial-Head Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, P. R. China;; Shanghai Key Laboratory of Stomatology, Shanghai 200011, P. R. China.
Yilong WangThe Institute for Translational Nanomedicine, Shanghai East Hospital, the Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai 200092, P. R. China.
Rong ZhouDepartment of Oral and Maxillofacial-Head Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, P. R. China;; Shanghai Key Laboratory of Stomatology, Shanghai 200011, P. R. China.
Zicheng DengThe Institute for Translational Nanomedicine, Shanghai East Hospital, the Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai 200092, P. R. China;; School of Materials Science and Engineering, Tongji University, Shanghai 200092, P. R. China.
Yong HanDepartment of Oral and Maxillofacial-Head Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, P. R. China;; Shanghai Key Laboratory of Stomatology, Shanghai 200011, P. R. China.
Xiao HanThe Institute for Translational Nanomedicine, Shanghai East Hospital, the Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai 200092, P. R. China;; School of Materials Science and Engineering, Tongji University, Shanghai 200092, P. R. China.
Wenjie TaoDepartment of Oral and Maxillofacial-Head Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, P. R. China;; Shanghai Key Laboratory of Stomatology, Shanghai 200011, P. R. China.
Zi YangThe Institute for Translational Nanomedicine, Shanghai East Hospital, the Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai 200092, P. R. China;; School of Materials Science and Engineering, Tongji University, Shanghai 200092, P. R. China.
Chaoji ShiDepartment of Oral and Maxillofacial-Head Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, P. R. China;; Shanghai Key Laboratory of Stomatology, Shanghai 200011, P. R. China.
Duo HongDepartment of Oral and Maxillofacial-Head Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, P. R. China;; Shanghai Key Laboratory of Stomatology, Shanghai 200011, P. R. China.
Jiang LiShanghai Key Laboratory of Stomatology, Shanghai 200011, P. R. China;; Department of Oral Pathology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, P. R. China.
Donglu ShiThe Institute for Translational Nanomedicine, Shanghai East Hospital, the Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai 200092, P. R. China;; The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH 45221, USA.
Zhiyuan ZhangDepartment of Oral and Maxillofacial-Head Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200011, P. R. China;; Shanghai Key Laboratory of Stomatology, Shanghai 200011, P. R. China.
Shanghai East Hospital · CNShanghai Jiao Tong University · CNStomatology Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In precision cancer nanomedicine, the key is to identify the oncogenes that are responsible for tumorigenesis, based on which these genetic drivers can be each specifically regulated by a nanovector-directed, oncogene-targeted microRNA (miRNA) for tumor suppression. Fibroblast Growth Factor Receptor 3 (FGFR3) is such an oncogene. The molecular tumor-subtype harboring FGFR3 genomic alteration has been identified via genomic sequencing and referred to as the FGFR3-driven tumors. This genomics-based tumor classification provides further rationale for the development of the FGFR3-targeted miRNA replacement therapy in treating patients with FGFR3 gene abnormity. However, successful miRNA therapy has been hampered by lacking of an efficient delivery vehicle. In this study, a nanovector is developed for microRNA-100 (miR-100) -mediated FGFR3 regulation. The nanovector is composed of the mesoporous magnetic clusters that are conjugated with ternary polymers for efficient miRNA

Indexed as

OncogenesAnimalsApoptosisBiological ProductsCarcinomaCell Line, TumorCell ProliferationCell SurvivalDisease Models, AnimalDrug CarriersHeterograftsHumansHydrogen-Ion ConcentrationMagnetite NanoparticlesMicroRNAsMolecular Targeted TherapyBiological ProductsDrug CarriersMagnetite NanoparticlesMicroRNAsMIRN100 microRNA, humanReceptor, Fibroblast Growth Factor, Type 3mesoporous nanovectormicroRNAoncogenePatient-Derived Xenograftsprecision medicine.

Identifiers

PMID28255359
PMCPMC5327642
OpenAlexW2574101718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.